Archives

Perfusfind S.L.

Abstract Background Veno-arterial extracorporeal membrane oxygenation (VA-ECMO) is a commonly used in refractory cardiogenic shock (CS) but may exacerbate left ventricular (LV) loading conditions and impair cardiac energetics. Adjunctive LV..

Perfusfind S.L.

Abstract Background Nearly 500,000 open-heart operations are performed annually in the United States, with complications such as postcardiotomy cardiogenic shock (PCCS) occurring in 2–9% of cases. Extracorporeal membrane oxygenation (ECMO)..

Perfusfind S.L.

Abstract Background Cardiogenic shock (CS) is a severe complication of ST-elevation myocardial infarction (STEMI) with high mortality despite advancements in treatment. Mechanical circulatory support (MCS) devices, such as extracorporeal membrane..

Perfusfind S.L.

Abstract In cardiogenic shock (CS), blood lactate concentration is routinely used to assess shock severity and guide clinical decisions. However, lactate interpretation is often oversimplified, leading to confusion between disease..

Perfusfind S.L.

Abstract Background Acute myocardial infarction-related cardiogenic shock (AMI-CS) remains associated with extremely high mortality in patients with acute myocardial infarction despite timely revascularization and advances in mechanical circulatory support (MCS)...

Perfusfind S.L.

Abstract The recent article by Ko et al., entitled “The effects of extracorporeal blood purification (oXiris®) in patients with cardiogenic shock who require VA-ECMO (CLEAN ECMO): a prospective, open-label, randomized..

Perfusfind S.L.

Abstract Weaning and liberation from V-A ECMO for cardiogenic shock involves complex decision-making that requires balancing multiple clinical parameters. In the absence of specific weaning guidelines, ECMO centers rely on..

Perfusfind S.L.

Abstract Background Cardiac surgery patients with severe preoperative left ventricular (LV) dysfunction are at high risk for poor postoperative outcomes including prolonged ventilation, renal failure and post-cardiotomy cardiogenic shock (PCCS)...

Perfusfind S.L.

Abstract This study aimed to investigate the heterogeneity of treatment effect for intra-aortic balloon pump (IABP) across various lactate trajectories in patients with acute myocardial infarction-related cardiogenic shock (AMICS) supported..

Perfusfind S.L.

Abstract This retrospective single-center study evaluated adults with cardiogenic shock supported with veno-arterial extracorporeal membrane oxygenation (VA ECMO) from 2011 to 2023 to identify predictors of in-hospital mortality among those..

Perfusfind S.L.

Abstract While cardiogenic shock (CS) is classically defined by primary cardiac dysfunction leading to impaired macrocirculatory variables—such as hypotension, reduced cardiac output (CO), and diminished left ventricular ejection fraction—growing evidence..

Perfusfind S.L.

Abstract Introduction:  In cardiogenic shock (CS), persistent microcirculatory impairment despite improved macrocirculatory parameters is associated with poor outcomes. Therapeutic strategies must therefore address both macro- and micro-circulation. Conventional microcirculatory measures..

Perfusfind S.L.

Abstract Importance To date, no studies have described the financial burden and behaviors of left ventricular mechanical unloading (LVMU) for patients on veno-arterial extracorporeal membrane oxygenation (VA ECMO). Given the..

Perfusfind S.L.

Abstract Background The prognostic significance of an adverse acid–base milieu despite venoarterial extracorporeal membrane oxygenation support in patients with cardiogenic shock remains poorly defined. We examined metabolic and respiratory disturbances..

Perfusfind S.L.

Abstract Background Landmark randomized controlled trials like DanGer Shock, IABP-SHOCK II, and ECLS-SHOCK guide infarct-related cardiogenic shock (CS) management with temporary mechanical circulatory support (tMCS), but strict enrollment criteria may..

Perfusfind S.L.

Abstract A less invasive paracorporeal single port pulsatile ventricular assist device (sppVAD) was developed for cardiogenic shock. This compact sppVAD includes a valved single lumen cannula (VSLC), valveless single port..

Perfusfind S.L.

Abstract Post-cardiotomy cardiogenic shock (PC-CS) affects 2–6% of cardiac surgery patients. While survival rates keep improving, 40% of intensive care (ICU) survivors experience a “post-intensive care syndrome”, encompassing physical, cognitive,..

Perfusfind S.L.

Abstract Introduction Temporary mechanical circulatory support (tMCS) has become essential in managing severe cardiac dysfunction, particularly refractory cardiogenic shock (CS). Despite widespread adoption, the optimal use of tMCS is often..

Perfusfind S.L.

Abstract Time is critical in the diagnosis and treatment of cardiogenic shock, even more so than in septic shock. Early identification enables prompt circulatory support and restoration of tissue oxygenation. Baseline..

Perfusfind S.L.

Abstract Background The microaxial flow pump (mAFP) has demonstrated improved outcomes in selected patients with ST-segment elevation acute myocardial infarction and cardiogenic shock (STEMI-CS). However, its use has been associated..

Perfusfind S.L.

Abstract The use of venoarterial extracorporeal membrane oxygenation (VA-ECMO) is increasing worldwide. Patients with cardiogenic shock were the first indication for VA-ECMO according to the Extracorporeal Life Support Organization (ELSO)..

Perfusfind S.L.

Abstract Cardiogenic shock (CS) remains a high-mortality condition that demands rapid diagnosis, coordinated multidisciplinary management, and timely initiation of mechanical circulatory support. As more institutions implement dedicated CS teams, substantial..

Perfusfind S.L.

Abstract Context: Veno-arterial extracorporeal membrane oxygenation (VA-ECMO) is a life-sustaining therapy for severe refractory cardiogenic shock. Although VA-ECMO provides various degrees of cardiopulmonary support, mortality rates remain high. Serum biomarkers have..

Perfusfind S.L.

Abstract Managing refractory cardiogenic shock is individualized, with few aspects considered routine or universally contraindicated. Venoarterial extracorporeal membrane oxygenation (VA-ECMO) is a temporary mechanical circulatory support strategy, providing hemodynamic stabilization..

Perfusfind S.L.

Abstract Dear Editor, The timely liberation of cardiogenic shock (CS) patients from veno-arterial extracorporeal membrane oxygenation (V-A ECMO) is crucial to reduce device  complications, although the predictor of weaning is..

Perfusfind S.L.

Abstract Importance  Levosimendan may facilitate weaning from venoarterial extracorporeal membrane oxygenation (VA-ECMO) and improve survival, but supporting evidence remains limited. Objective  To assess whether early administration of levosimendan reduces the time to..

Perfusfind S.L.

Abstract Background For decades, the intra-aortic balloon pump (IABP) has been a reliable and readily available pillar of therapy for cardiogenic shock (CS). However, no clinical markers have been validated..

Perfusfind S.L.

Abstract Background Immediate initiation of extracorporeal membrane oxygenation (ECMO) has not demonstrated benefit in individuals diagnosed with cardiogenic shock based on the presence of hypotension. The relationship between other hemodynamic..

Perfusfind S.L.

Abstract Objective To construct a nomogram prediction model for death in patients with cardiogenic shock after extracorporeal membrane oxygenation (ECMO) weaning. Methods Totally 210 patients with cardiogenic shock treated with..

Perfusfind S.L.

Abstract Background: The use of temporary mechanical circulatory support (tMCS) has revolutionized the management of cardiogenic shock (CS). However, standardized readiness-to-explant criteria for venoarterial extracorporeal membrane oxygenation (VA-ECMO) have not been..